Antidiabetic Drugs Library
Antidiabetic Drugs DMPK and Bioanalytical Services
Antidiabetic drug bioanalysis is defined not by a single analytical hazard but by analytical breadth unmatched by any class in this library. Eleven compounds span two modalities — 10 small molecules and one biologic (insulin) — and require five distinct analytical approaches: CYP Phase I (glipizide, glyburide, pioglitazone, saxagliptin), UGT Phase II glucuronidation with SGLT2 pharmacologic target context (canagliflozin, empagliflozin, dapagliflozin), transporter-mediated renal disposition (metformin: OCT2/MATE), non-metabolized unchanged-parent quantification (phenformin, sitagliptin), and protein-level bioanalysis for a biologic (insulin: protease catabolism). A β-NADPH-supplemented microsome incubation — the default for almost every preceding page — is correct for four compounds, partially applicable to three more, and irrelevant to the remaining four.
Creative Proteomics provides CYP Phase I metabolism for sulfonylureas and gliptins, UGT Phase II SGLT2-targeted glucuronidation profiling, transporter-mediated disposition analysis, non-metabolized compound quantification, protein-level bioanalysis for insulin, and custom multi-class antidiabetic panels.
Insulin: First Biologic in This Library51-amino-acid protein requiring ligand-binding assay or LC-MS surrogate peptide bioanalysis — not small-molecule methods.
SGLT2 Inhibitors: Phase II + TargetCanagliflozin, empagliflozin, dapagliflozin: UGT Phase II with SGLT2 target context. Low-clearance profile distinct from CYP substrates.
Three Routes to Non-Metabolic ClearanceMetformin (OCT2/MATE renal), phenformin (excretion), sitagliptin (Minimal Met) — bypass CYP and UGT entirely.
Antidiabetic Five-Domain Map DMPK Strategy Map
⚡
Five Analytical DomainsCYP Phase I (NADPH), UGT Phase II SGLT2 (UDPGA), transporter disposition, non-metabolized excretion, and biologic protein bioanalysis — no shared incubation protocol across all 11 compounds.
🧬
CYP Phase I (4 compounds)Glipizide/glyburide (CYP2C9), pioglitazone (CYP2C8/3A4), saxagliptin (CYP3A4/3A5) — standard NADPH-supplemented microsome incubation.
📊
UGT Phase II SGLT2 (3 compounds) + Biologic (1)Flozins: UGT1A9/2B4/2B7 glucuronidation with low-clearance profiles. Insulin: protease-mediated protein catabolism.
🔬
Transporter & Non-Metabolized (3 compounds)Metformin: OCT2/MATE renal. Phenformin: excretion unchanged. Sitagliptin: Minimal Met, renally excreted. No CYP or UGT needed.
Antidiabetic domain audit before method development.Creative Proteomics classifies each compound into one of five analytical domains — because insulin requires protein bioanalysis, metformin requires transporter profiling, and glipizide requires CYP2C9 incubation — five mutually exclusive analytical approaches within one therapeutic class.
